News | August 12, 2024
Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
